Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Refractory Aplastic Anemia
NCT07287228Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT07287228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287228.